AbCellera Biologics Inc.
ABCL
$4.18
-$0.12-2.79%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -165.67M | -167.87M | -162.86M | -175.80M | -153.30M |
| Total Depreciation and Amortization | 33.86M | 64.84M | 65.00M | 92.21M | 61.32M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 48.13M | 13.03M | 15.15M | 2.76M | 27.04M |
| Change in Net Operating Assets | 2.83M | 11.60M | -25.84M | -39.34M | -26.45M |
| Cash from Operations | -80.84M | -78.40M | -108.56M | -120.17M | -91.39M |
| Capital Expenditure | -58.15M | -64.89M | -78.40M | -77.20M | -79.01M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 73.67M | 164.33M | 199.81M | 138.58M | 123.91M |
| Cash from Investing | 15.53M | 99.43M | 121.41M | 61.38M | 44.90M |
| Total Debt Issued | 20.65M | 17.98M | 14.85M | 13.98M | 17.44M |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 227.00K | 227.00K | 227.00K | 227.00K | 256.00K |
| Repurchase of Common Stock | -1.58M | -1.58M | -1.58M | -1.08M | -1.08M |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -9.42M | -722.00K | -729.00K | -737.00K | -739.00K |
| Cash from Financing | 9.88M | 15.91M | 12.77M | 12.39M | 15.88M |
| Foreign Exchange rate Adjustments | -442.00K | -1.25M | -2.62M | 611.00K | -819.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -55.88M | 35.69M | 23.01M | -45.78M | -31.43M |